Claim Ownership


Subscribed: 0Played: 0


These days many sources are highlighting the shocking scale of the global mental health crisis and how this affects approx—a staggering one billion people worldwide - over one-seventh of the global population.“Unfortunately, as harrowing and monstrous this number is”, the investor Christian Angermayer wrote in a blog post, “it is my belief this is a gross UNDER-estimate.”Ultimately, the number of people needing mental health support is arguably all 100% of the world's population.I invited Dr. Jonathan Sporn, CEO of Gilgamesh Pharmaceutical, to gain more insights into the unmet medical need in mental health and the promising novel psychedelic drug development sector Jonathan Sporn MD is a Board Certified Psychiatrist, assistant professor at Columbia University, and CEO of Gilgamesh Pharmaceuticals, based in NYC, which is developing novel psychedelic-related or inspired medicines to treat mental illness.Topics we discuss in this episode:➡️ Global Mental Health Situation➡️ The History of Psychedelic Drug Development➡️ Investors in this promising area➡️ The Background Story to the foundation of Gilgamesh Pharmaceutical and➡️ And the Different Ingredients Needed to Structure a Novel Game-Changing Drug Development CompanyConnect with Jonathan Sporn on LinkedinYoutube Video🕒  Timestamps:(00:00) Introduction to Topic, Speaker, and Company(04:00) Life in New York in 2022(07:15) The Global Mental Health Pandemic (10:39) Mass Shootings in the United States as a result of the Mental health Situation(14:05) Why is it Necessary to Develop Novel Drugs to Fight Mental Health Issues in Society (19:00) The History of Drug Development for Mental Health Patients(24:00) How Effective Are Psychedelic Drugs to Tackle Mental Health Questions?(25:05) Psychedelic Drugs in Pop Culture(26:40) What Inspired Jonathan Sporn to Dedicate His Professional Life to Advance R&D in Psychedelic Drugs(29:30) Psychedelic Drugs Help to Observe Own Behaviour(32:30) Root Causes of Mood Disorders like Maniac Depression, Bipolar Disorder(34:05) Psychedelic Drugs Enhance Neuroplasticity(36:50) From Basic Research to Drug Development in the Pharma Industry(40:10) Mental Health R&D at J&J(43:40) S-Ketamine vs. K-Ketamine – Difference and Similarities(46:35) Early-Stage Research in Big Pharma(49:00) Big Pharma and Small Biotechs(51:50) The decision to Start A New Company(57:00) Foundation of Perception Neuroscience – From Early Stage Research to Clinical Phase 2 to Exit (59:05) Atai Life Science – Continuing Development of the Compounds against DepressionSupporting links: (01:00:00) Reasons for Becoming a Serial Entrepreneur After a Successful Exit Deal(01:06:00) Drug Development is Simple – Given an Experienced Drug Development Team(01:08:00) What is the unique approach of Gilgamesh Pharmaceutical?(01:10:15) Target Product Profile of Psychedelic Drugs (01:20:30) Gilgamesh Pharmaceuticals Mission and Vision(01:23:20) Patents in Psychedelic Drug Development(01:24:45) Business Model of Gilgamesh Pharmaceutical(01:29:00) Artificial Intelligence in Psychedelic Drug Development(01:33:14) Investing in the Psychedelic Drug Development Industry(01:37:22) Life Science VCs in the Psychedelic Drug Development Industry(01:39:00) Christian Angermayer, Peter Thiel, Mike Novogratz – Investors in Psychedelic Drug Development(01:41:00) Investment Sentiment in the United States in Developing Novel Innovation(01:43:00) Opinions on the Investment Market Situation in 2022+(01:49:40) Gilgamesh Pharma Plans for the Coming YearsSupport the show
Warren Buffett recommends buying companies with a great moat. Something that makes the company unique and protects the business from the competition. Patents are the best moats. Do you want to know why? Then listen to Gerda Redl.Who is the speaker?Dr. Gerda Redl is a patent attorney with more than 20 years of experience in the life sciences industry.Her technical expertise is in biotechnology, biochemistry, and chemistry, including protein engineering, biologicals, small molecules, biomarkers, antibodies, alternative scaffolds, and libraries.Before founding REDL Life Science Patent Attorneys, she held senior management positions in biotech, mid-size, and big pharma companies. She graduated as a biochemist and received her Ph.D. in microbiology from the Technical University of Vienna.Topics we discuss in this episode:➡️ The Value of Patents ➡️ Fast Track Protection➡️ Key Territories in a globalized World ➡️ Digitalization ➡️ Interdisciplinary InventionsYoutube: 🕒  Timestamps:(00:00) Kick-Off(04:33) Patents are Assets(06:40) Different Types of Patents and their Economic Value(12:56) Product or Platform Technology Patents – Case Study mRNA Vaccines(15:38) When is the Right Time to File Patents?(18:55) In What Cases Are Patents not Necessary?(20:06) Patents, Trademarks, and Know-How(21:22) Patent Filing and Deal Structuring – What is The Right Sequence of Events?(22:13) What Confidentiality Agreements can and cannot do(23:55) What is the perfect patent solution?(27:20) Time and Capital Needed for Filing and Maintaining Patents(31:05) The Best Patent and Business Development Strategy for Scientific Founders(34:00) What territories should be protected?(43:04) What effects have restrictive patent laws on motivating entrepreneurs to turn scientific inventions into products?(45:15) How Patents Drive Investment Processes(47:30) How to Overcome Patent Hurdles when third parties don’t want to commercialize their patents.(52:45) Possibilities of Speeding Up Patent Processes(58:29) China – The Innovation Leader of the World(01:00:41) The FTO Jungle(01:01:35) Acceleration of Patent Processes(01:02:00) Digitalization of Patent Processes(01:05:00) AI-based translations of Patents(01:09:00) Unitary Patents in Europe(01:17:45) The Convergence of Technologies and Patents(01:23:31) What is First: Product Concept or Patent?(01:25:00) First Step Towards Filing the First Patent Application(01:27:35) It is About the People…Podcast Links:Podcast Community: Partner: Soschner: Linkedin: Episodes: the show
What is going on in the world of digital assets in 2022? In May 2010, 10,000 BTC bought 2 Pizza. Last year in November, the same amount had a value of 600 Million dollars. A lot has evolved since 2010 in the digital asset ecosystem.That's why I asked Alexander Valtingojer, CEO of Coinpanion, to discuss the latest development in the crypto market. This episode was recorded in January 2022. What are the topics we discuss in this episode?Digital Natives and the Boomer GenerationBitcoin and other CryptocurrenciesThe Biggest Wealth Transfer in Human HistoryNFTs, Web 3 and the MetaverseAnd much, much more 🎙️ Youtube: in this episode: Ray Dalio, The Changing World Order🕒  Timestamps:(00:00) Intro(03:30) South Tyrol – Cultural Background(06:00) The Development of Digital Assets in Q1/2022(10:00) Long Term Perspective of the Crypto Eco-System(17:30) The Future of NFTs(20:45) What NFTs can do for books(25:30) What Are Smart Contracts?(27:45) Remodeling the Book Industry with Smart Contracts(30:30) Interoperability(31:30) Use-Cases for NFTs in the Creator Economy(38:00) NFT become Commodities(39:30) A Brief History of Smart Contracts(41:30) Tokenized Shares(45:30) How Regulation Helps the Ecosystem(47:08) Web3 and the Metaverse(52:30) Star Trek, Ready Player One, Mark Zuckerberg and the Metaverse(54:30) Lex Friedman – What Happens When an AI becomes conscious?(58:15) The Mission of Coinpanion(01:02:06) The Story Behind the Foundation of Coinpanion(01:04:30) The Investment Approach of Coinpanion(01:10:30) Bitcoin(01:16:30) The Biggest Generational Wealth Transfer in the History of Human Society(01:18:30) Use Cases for Gold(01:20:30) NFTs, Collectibles, and the Gaming Industry(01:24:30) Maker and DeFi(01:26:30) Ethereum(01:30:30) Charles Hoskinson, Cardano, and ADA(01:31:50) Polkadot and Link(01:35:50) Uniswap(01:37:57) USDC(01:40:30) Stablecoins, Stacking, and Default Risk(01:45:30) Coinpanion helps with investing in Digital AssetsPodcast Links:Community Partner: Soschner: the show
How Did the Conference Industry Change in the last two years? Philadelphia in 2019 was the last Bio I attended in person. In March 2020, the world shut down to respond to the novel viral threat. Since then, all conferences have been digital.  What effect did this have on the conference Industry – especially the Bio US? Listen to Rich Masters, Chief Public Affairs and Marketing Officer of Bio.As EVP for Public Affairs, Rich Masters leads integrated communications, branding, and marketing strategy for the organization, including overseeing the policy communications that support the advocacy goals across each of BIO’s sections. What are the topics we discuss in this episode?What are Bio and the Bio US 2022?How Did the Conference Industry Respond to the Lockdowns?The Availability of Capital for InnovationEntrepreneurship in the United States andWhat’s New at the Bio US 2022 📚 The Emperor of All Maladies📰  Article:  Medium 🎙️ Youtube: Register today:🕒  Timestamps:(00:00) Intro (01:36) Who is Rich Masters(02:54) What is Bio?(03:30) Opening(04:30) How is The Situation in the United States with the Pandemic These Days?(05:40) How did the Pharma Industry Respond to the Global Viral Threat?(06:00) How did BIO Help Solve the Biggest Healthcare Challenge in the last 2 years?(08:33) What Is Biotechnology Innovation Organisation (BIO)? It is not only the Bio US.(12:10) How is the Availability of Capital for Biotechnology Product Development in the United States?(14:20) What Are The Bio Business Solutions and how does it help SMEs?(15:43) Is a BIO Membership for US Companies Only, Or is it Open for European and Asian Companies?(17:40) Entrepreneurship in the United States for Bio Product Development(18:24) Where are the Bio Hotspots in the US?(19:15) The Different Sides of BIO(20:15) Big Trends in Bio in 2022(26:20) What A Convention Model Looks Like in a Post Pandemic World(31:35) Taking the Best of Two Worlds - New On-Demand Service – All Panel Discussions, Presentations, and Speeches in One Digital Space(33:35) Bio Impact in Omaha, Nebraska(36:05) Are Digital Conferences a Replacement for Real-Life Versions?Add on Services at the Bio:(40:00) The Midway Experience in San Diego(41:00) I am Bio(42:05) Bio US Podcast – I am Bio(42:30) Good Day Bio(42:45) Bio.News(44:25) Challenges for Conference Organizers that Came with March 2020(41:30) How Bio Helps their Members to Overcome Challenges Ahead  Especially the SMEs(55:35) Side Events at The Bio to Meet and Mingle with the Industry (58:25) Limitless - Rich Masters – See You on June 13-16 in San Diego to Celebrate the Work of ScientistsPodcast Links:Community Partner: Soschner: LSG2G Partners Experts in Life ScienceSupport the show
Are you interested to expand your business into Asian Markets? Then this episode might be for you. As Program Manager of the Global Incubator Network Austria (GIN), Lisa Stöger has successfully connected the Austrian startup ecosystem with the world's most innovative startup hubs for the last 4 years. With a focus on Asian markets, she supports Austrian startups in their internationalization and market entry and introduces them to relevant, international stakeholders. Since 2016, GIN, co-managed by AWS and FFG, has been the contact point for startups regarding expansion from Austria to Asia and vice versa. Over 300 startups have benefited from the customized GIN services and internationalization programs. With her interdisciplinary academic background in Politics and Economics in Vienna and York (UK), Lisa is passionate about identifying cooperation potentials between international organizations and public institutions and is eager to apply these to promote startups and boost innovation.  What are the topics we discuss in this episode?We cover 7 different eco-systems in Europe and AsiaAustriaIsraelChinaHongkongSingaporeJapan and South Korea 🎙️ Youtube:🕒  Timestamps:(00:00) Opening(02:18) What is GIN?(05:00) Connecting the Start-up Eco-Systems in Europe with Asia(07:05) How Did the Pandemic Change the Way People Are Doing Business in the Startup Eco-System(10:30) The Potential of the Digitalisation in Creating New Business Relationships(14:04) The Start-up Eco-System in Israel – Linking Europe with Asia(17:05) Go Global Out of the Israeli Eco-System(18:05) The Start-Up Hub in Tel Aviv(22:05) The Silicon Wadi in Israel (24:40) Availability of Venture Capital in Austria(27:00) The Availability of Venture Capital in Austria for Companies Raising Series A Rounds and Beyond(29:15) Mainland China(33:57) How to Overcome the Language Barrier in Business(38:15) Contracts – Is English Sufficient?(39:06) The Eco-System in Singapore(41:22) The Tax Rates in Singapore(42:00) Singapore – The Gateway to South-East Asia(40:30) Startups in Hong Kong(45:00) Should Startups Create Subsidiaries in foreign Eco-System to gain more credibility?(51:53) The Start-Up Eco-System in Japan(55:15) The Japanese Business Culture(56:34) South Korea and Startups(57:18) The Business Culture in South Korea(01:01:34) The Covid Strategy in South Korea(01:06:25) What is the best first step into Asian markets?(01:08:35) Why Should Startups consider an entry into Asian Markets?Podcast Links:Podcast Website: Community: Partner: Soschner: Twitter: Linkedin: Episodes: the show
Do you want to know why networking and leadership are so important to be successful in business? And why everybody, including employees, needs to learn those skills? Then this episode is for you. Mark is the author of The Career Toolkit, Essential Skills for Success That No One Taught You. Educated at MIT, Mark has spent his career launching and fixing new ventures at startups, Fortune 500s, and academia. He’s developed new software languages, online marketplaces, new authentication systems, and tracked criminals and terrorists on the dark web. Mark helped create the Undergraduate Practice Opportunities Program, MIT’s “Career Success Accelerator”, where he’s taught for twenty years. Mark also serves on the boards of non-profits Techie Youth and Plant a Million Corals. 📚 The Career Toolkit: we cover in Episode Number 74:➡️  Leadership➡️  Entrepreneurship➡️  What is Better: Alpha or Beta Leaders?➡️ What Makes Exceptional Leaders like Elon Musk, Bill Gates or Steve Jobs?➡️  And much much more🎙️ Youtube:🕒  Timestamps:(00:00) Intro(02:00) How has life been on the East Coast in January 2022?(03:00) Travel Restriction and Mask Mandates in 2022(05:30) Why Was it Necessary to Write “The Career Toolkit”?(07:02) The 10 Most Important Skills For Entrepreneurs(08:15) Why Are Those 10 Skills Not Taught at Universities?(11:00) What is Leadership?(13:15) Leadership and Influencers: What is the Difference in the skillset?(15:30) Is Leadership Learn- and Teachable?(17:45) Management and Leadership – What is the Difference?(20:32) Alpha Male and Beta Male – What is Better for Leadership in this Century?(23:30) Why Situational Leadership Matters(28:15) Character Traits of Exceptional Leaders Like Elon Musk, Steve Jobs, or Bill Gates(30:00) Leadership – Is it the Ceos' Job or also the duty of the Employees?(32:15) If you want to lead from the front, you must first learn to lead from behind(31:53) The Importance of Networking for Entrepreneurship(38:36) The Role of Networking for Fundraising Entrepreneurs(44:15) The Secret of Building and Maintaining Relationships(48:15) The Power of Introductions in Networking(49:43) Do Introduction Substitute the Relationship Building Phase?(51:45) Why Real Life Still Matters in Relationship Building(56:00) What Can and Cannot be done via Zoom During the Relationship Building Phase(01:02:36) The US Startup Eco-System in 2022(01:06:30) What is the best way to approach the startup ecosystem in the US as a startup?(01:11:15) What is the US Eco-System Looking for in Startups?(01:14:30) The Big Vision – Why it Matters and Why Not(01:16:30) What is the best way to engage with the US Eco-System(01:17:40) Professional Background of Mark Herschberg and How you Can Reach Out to HimPodcast Links:Podcast Community: Partner: Soschner: Linkedin: Episodes: LSG2G Partners Experts in Life ScienceSupport the show
Do you want to know how to value a company and what Julia Roberts has to do with it? Then listen to Bharat Kanodia in this episode number 73.Valuation is one of the most difficult exercises in the startup world. How can you put a price tag on a company that doesn’t exist yet? Get help from an expert: Bharat Kanodia has valued over 2000 businesses and signed off on assets worth $2.6 trillion in value. He has appraised unique assets like the Golden Gate Bridge, Atlanta Airport, Uber, Airbnb, Yahoo!, Brooklyn Bridge, Mirage Casino LV, among many others. Bharat is the Founder of Veristrat, a company that helps startup founders and VCs by telling them what their companies are worth. He lives in the San Francisco Bay area with his family and enjoys sailing, golfing, skiing, and horseback riding. In this episode number 73 we are talking about:➡️  The History of Entrepreneurship in San Francisco➡️  Failure Culture➡️  Julia Roberts➡️  NFTs➡️  And much much more...Books mentioned in the Podcast:Epic Businesses: Habits: Do you want to reach out to Bharat Kanodia:LINKEDIN: INSTAGRAM: http://www.veristrat.comFACEB00K: Speech:📝 Shownotes: tbd🎙️ Youtube:🕒  Timestamps:(00:00) Intro Bharat Kanodia(04:00) History of Entrepreneurship in San Francisco(07:08) Failure Culture on the West Coast(08:40) The Startup Reality – 9 out of 10 attempts fail (10:10) Veristrat – Corporate Valuations(11:30) The Nature of Valuations(15:31) How to Deal With Valuations in the Startup World?(20:00) Valuating Companies on a Pitch Deck Basis(26:50) Beeple’s Everydays NFT – How to Put a Price Tag on It(32:00) The Valuation of Cryptocurrencies(35:34) How to Put a Price Tag on Early Stage Drug Development Companies(40:00) When Should Founders Start to get Professional Support for evaluating the company and their products?(43:35) How to Put a Price Tag on Landmarks like the Eiffel Tower(45:10) Life Habits of Successful Entrepreneurs(47:00) Atomic Habits(49:15) How to Reach Out to Bharat KanodiaPodcast Links:Podcast Website: Community: Partner: Soschner: Twitter: Linkedin: Episodes: on YouTube: the show (
Do you want to reach out to Japanese companies and universities? Then you should know what makes Japan special and different to have a smooth business experience.Different Cultures – Different Rules and Different ways to successJapan is the second biggest market for pharmaceuticals globally. The area is not only interesting for its sales potential; it is also a major R&D hub in Asia.One of the best experts in Japanese business culture in the LSG2G Community is Stefan Sandström.Stefan Sandström is a serial entrepreneur who lived his first life in Sweden and is now living his second life in Japan. Instead of entrepreneurship, he's set up a business development consultancy in Japan aiming at the biopharma industry. After 15 years in Japan and partnering with Mr. Kuboniwa (retired from Chugai, chairman of the management committee of JBA, Japan Bioindustry Association, chairman of GTB, Greater Tokyo Bio community, and an advisor for the Japan Government), we always help find the best solutions in increasing traction or finding the right partners.We are talking about:➡️ Japanese Martial Arts➡️  How is daily life in Japan➡️  Japanese Meeting Culture➡️ The Role of Informal Meetings and➡️ How to Negotiate Prices in JapanDo you want to get in touch:⏩  Stefan Sandström:⏩  Manifestum AB:📝 Shownotes: tbd🎙️ Youtube:🕒  Timestamps:(00:00) Introduction(02:00) Kick-Off and Greetings to Yokohama(03:15) The Covid Situation in Japan January 2022(05:13) Reasons to Move to Japan(06:20) Kendo and Japanese Martial Arts(08:12) Martial Arts and Business(12:07) What Makes the Japanese Business Culture So Unique?(18:55) Daily Life in Japan(27:30) What are the 3 most important things everybody needs to know before traveling to Japan?(30:50) How Important is it to build business relationships in Japan?(32:40) Business Background Stefan Sandström(35:53) What is the Right Way to Engage with Japanese Companies? – A Case Study(41:45) Japanese Meeting Culture – What are the differences between formal and informal meetings?(43:45) Mind not only what happens in meetings but also what doesn’t happen in meetings(45:15) What does it mean when in subsequent meetings, similar questions are asked?(48:17) How is it perceived to change meeting dates on short notice?(51:55) How to set up informal  meetings in Japan(58:50) How to Negotiate the Price in Japan(01:01:00) What is the best first step in creating business relations with Japanese companies?Podcast Links:Podcast Website: Community: Partner: Soschner: Twitter: Linkedin: Episodes: on YouTube: the show (
Did you know that almost 90% of all product ideas fail in clinical trials?  Surprising to me was that lack of efficacy doesn't seem to be the main reason why clinical trials fail in the first place. Other factors are at play, and most of them are manageable risks when the right team is at work.In this episode:Strategic considerations for setting up a clinical trialInhouse vs Outsourced Clinical Study ManagementWhy  clinical trials failSteps to getting your clinical trial back on trackFuture trends of clinical trialsWho is the expert in the show?Heike Schön,  Lumis International GmbH with more than 25 years of experience in international clinical research and drug development. 📞 Book a meeting here: Link📰  Article: MediumYoutube: notes: LinkTimestamps:(00:00) Intro(02:25) Who Is Heike Schön, Lumis International and Lumis Consulting?(04:20) Topics in the Episode(04:30) Kick-Off(05:00) Background to Lumis International and Heike Schön(10:20) When is the Right Time to Start with the Planning of a Clinical Trial?(12:10) The Role of a Sponsor of a Clinical Trial(14:30) Who is Responsible for the Clinical Trial as a Sponsor?(16:55) When Should a Company Start to Implement Clinical Trial Management in the Organisation?(18:30) Funding Requirements for Clinical Trials(20:00) The Reality of Inhouse and Outhouse Clinical Trial Management(22:15) What to Think About When Planning Oversight Management(25:00) Relationship and Culture Management in Clinical Trials(27:25) Budget and Ressource Requirement for Clinical Trials(28: 45) 3 Steps to a Successful Clinical Trial (30:40) The 3 Main Reasons Why Clinical Trials Fail(33:30) Considerations for Patient Enrollment as a Key Success Factor for Clinical Trials(37:30) … and when enrolment fails, what are the steps to rescue the trial?(42:45) Do Inhouse Studies Require Rescue?(44:30) How to Rescue a Clinical Trial(48:30) Root Cause Analysis as a Starting Point to Rescue a Trial(52:25) Preventive Measures to Avoid Failure Early on(53:30) How Important is Leadership in a Clinical Trial?(56:30) The 3 Main Reasons to Stop a Clinical Trial – The Point of no Return(59:00) How are the Cost Calculated for Rescue Study Management?(01:00:15) Planning of a Clinical Trial – A Key Aspect of a Successful Trial(01:02:15) How to Plan Realistic Timelines and Numbers(01:07:15) The Role of Feasibility Studies in Clinical Trials(01:09:30) How Clinical Trial Management Evolved in the last 30 years(01:11:15) Upcoming Trends in Clinical Trial Management(01:13:15) Decentralized Clinical Trials(01:15:00) Artificial Intelligence And Big Data in Clinical Trial Management(01:17:55) The Digital Twin(01:19:15) The Human Factor and Leadership in Clinical Trial Management(01:21:10) The Patient in Clinical Trials(01:22:55) Planning and its contribution to clinical trial success(01:26:55) Summary of What to Do When Clinical Trials Fail(01:28:35) When is the Right Time to Add a Rescue Team to the Clinical Trial?(01:31:00) A Risk Management Plan for Clinical Trials(01Support the show
Big corporations strive to bring new solutions to their customers to help them solve their most pressing problems.To do so the corporation needs to be innovative. That's why companies like Apple, Google, Pfizer, and similar players want to cooperate with start-ups and scale-ups globally.Such cooperations strive to collaborate with top startups, invest in them, and sometimes acquire them to have access to novel ideas. By innovating the big players stay competitive, secure growth, and also help keep their employees motivated and curious.One of the best ways to foster innovation is creating Venture Capital funds. Venture funds collect capital to invest in high-risk early-stage innovative startups to help them grow.In this episode, we talk about:Why is Venture Capital important for Innovation in Life Science?What is the Secret Sauce of Venture Capital?Venture Capital Success StoriesWhat is the Current Situation of Venture Capital in Europe?And much moreWho is the expert in the show?Bruno Montanari is a Partner at Seroba. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology, and medical device industries.Bruno sits on the boards of STORM Therapeutics and Coave Therapeutics.Youtube: Introduction(03:30) Start of the Conversation “How Venture Capital Supports Science & Innovation”(03:45) What is Venture Capital?(07:30) Why is Venture Capital Necessary?(08:35) How Capital Intensive is Drug Development in Life Science?(11:55) Why Do Research Organisation and Big Pharma Need Companies in Between the Value Chain?(17:15) How Much Capital is Needed to Bring a New Therapy to the Market?(19:10) Why do some Life Science Start-Ups Fail?(24:30) How Can Venture Capital Help to Build Europe Into a Startup Continent?(31:53) How Innovation Changes the World(32:40) The Entrepreneurship Mindset between Academia and Industry(36:45) The State of Venture Capital in Europe(39:00) Elements Needed to Develop the Life Science Industry in Europe(42:35) Why Do Life Science Companies in Europe get Listed on the NASDAQ?(49:00) The Advantages of Specialized Investors(50:50) Benefits for Family Offices and High Networth Individuals to Invest in a Venture Fund Rather than directly into early-stage startup companies (59:00) Seroba Life Sciences(01:00:40) Success Stories from the Venture Capital Life(01:06:15) What kind of Deals are VCs looking for?(01:09:15) The Importance of Gathering Information before Closing a Deal – on both sides of the negotiation table(01:14:10) How to Balance Pitching and Relationship Building (01:19:30) 2x/10x/100X – Why are these metrics important to VCs(01:23:30) Deal Closed and they lived happily ever after – How does life look like post-investment?(01:27:00) How VCs Support Their Portfolio Companies(01:31:35) Warren Buffett vs. Venture Capital – Why is an Exit Important to VCs?(01:39:00) How to Reach Out to Bruno Montanari and Seroba Life SciencePodcast Links:Podcast Community: Partner: Soschner: Episodes: the show (
Lately, investors and researchers have published more and more information on longevity research and development. Investors like Sergey Young or  Christian Angermayer started to bet significant capital on this topic. What is going on in this field on the research side? What are potential applications to increase the Lifespan? And when will those innovations hit the market?In this episode, I had a conversation in December 2021  with Prof. Collin Ewald, ETH Zürich, about his longevity research and the future impact on the pharma industry.In this episode, we talk about: What is the role of the extracellular matrix during aging and longevity? Where is currently the innovation for longevity drug discoveries done? What aging research is going on?The Swiss Society of Ageing and Longevity Research And much more…Who is the expert in the show?Prof. Ewald is Head of the Extracellular Matrix Regeneration Laboratory, Department of Health Sciences and Technology.Collin has a longstanding interest in the molecular biology of healthy aging and age-related pathologies.He is the founder and currently the president of the Swiss Society for Aging Research ( He is named under the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland. He has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences.Youtube: Opening about the situation in Switzerland and Austria in December 2021(05:40) Longevity, Ageing, and the Health Span(07:05) Collin Ewald – Development of Ageing Research since the 90s(10:45) What is Ageing?(16:45) What is the Possible Lifespan of Human Beings? From Stone Age to the Future(20:10) What Factors Changed in Society that helped increase the average Lifespan?(22:45) The Importance of Education on Healthy Aging(26:15) How Education and Research Evolved with the Internet(27:00) Research Focus of the Collin Ewald Lab(33:30) Doubling the Lifespan in lab trials – is it possible to translate the research into human applications?(35:40) How to Translate Research into Products with Spin Outs.(38:00) Spin Outs from the Collin Ewald Lab(47:24) The Role of Extracellular Matrix in Ageing(54:40) The Potential for Applications for Cancer Diagnostic rooted in the research of the Collin Ewald Lab(56:15) How Artificial Intelligence Helps in Research(59:45) The Challenges Longevity Drug Development Faces at the Clinical Stage(01:03:45) The Role of Food & Science in Longevity Research (01:07:45) The Swiss Society of Ageing Research & Health Policies(01:13:00) Development of Life Expectancy(01:17:20) Healthy Ageing and Social Security(01:20:25) Advice to Young People Who Want to Create Lasting Change(01:25:35) The Killer Experiment - How Failure Creates SuccessPodcast Links:Podcast Community: Partner: Soschner: Linkedin: the show (
What significant problems does the food industry face today? Which solutions are already in development? In this episode, I am talking with Mauricio Agudelo and Lina María Toro about Sustainable Food Innovation in South America. BIALTEC assists animal protein producers to improve productivity and profitability through precision nutrition, understanding their particular dietary needs, analyzing them through a bioinformatics platform that uses artificial intelligence, and supplying the next generation antibiotic-free additives that will facilitate performance to obtain the desired results.In this episode, we talk about:The Problems in the Food Industry What Solutions are in Development?Bialtec’s MissionWhy You Should Create a Startup andMuch MoreI hope you enjoy the conversation the same way I did.Who are the experts in the show?Mauricio Agudelo (eMail:  Lina María Toro (eMail: tbdYoutube: Intro(02:30) Opening(05:45) Recap of EFIB October 2021(09:15) The Major Problems in the Food Industry in South America, North America, and Europe(11:40) Use of Antibiotics in Agriculture (12:45) The Two Big Problems in Agriculture (13:45) Precision Farming and Precision Agriculture: Using AI, Big Data and Gene Editing(16:20) Bialtec’s Mission(19:50) Solution of Bialtec for Precision Farming(24:15) The Importance of the Microbiome(30:20) Big Data, Health, and Nutrition(31:50) Let Food be thy medicine and medicine be thy Food.(33:30) The global increase in meat consumption(36:15) Sustainability(38:30) Motivation to create a StartUp(46:45) The Start-Up Eco-System in Colombia(50:45) Live Your Dreams(54:00) Opportunity for US and EU Bases Investors in Latin America(58:45) Bialtec’s Plans for European Expansion(01:01:45) What is Bialtec Looking for?Podcast Links:Podcast Website: Community: Partner: Soschner: Twitter: Linkedin: Episodes: on YouTube: the show (
Innovation needs collaboration on a global scale. Making things happen requires entrepreneurs who love science and work day and night to connect the best minds globally and support them to translate their science into products and businesses.In this episode, I have a conversation with Kai Lamottke, CEO and Co-Founder of Bicoll.Dr. Kai Lamottke is co-founder & CEO of Bicoll GmbH and Bicoll Biotechnology (Shanghai) Co. Ltd., the first German-Chinese biotechnology company. His expertise and knowledge in life science and innovation sectors in China and Europe are requested by corporates, SMEs, and organizations, like European Commission. The excessive network of business, academic and political contacts allowed him to achieve business governmental grants with a value of over 23 Mio. € up to now The Bicoll Group is a privately-owned biopharmaceutical company which includes Bicoll GmbH headquartered near Munich in Planegg / Martinsried, Germany, and its wholly-owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd.In this episode, we talk aboutFrom Science to BusinessBicoll’s MissionFinding the Business ModelHow to Establish Business Between ContinentsOperating in a Pandemic WorldI hope you enjoy the conversation the same way I did.Who is the Expert in the show?Kai LamottkeBicollShownotes: to the Episode: Start(02:30) Science During the Pandemic(07:05) Introduction Kai Lamottke and Bicoll(13:00) Entrepreneurship(17:30) Bicoll’s Mission(19:50) The Process of Finding a Business Model – Example Bicoll(25:00) World of Entrepreneurship(29:15) The Magic of Drug Discovery(35:00) How to Deal with Failure(41:00) How to Start a Company in China(47:45) Founding Companies in Asia at the beginning of the Millenium(51:45) How to Communicate Across Continents Without Social Media, Smartphone and Highspeed Data Highways?(57:45) Managing International Business in a Pandemic World(01:01:30) Similarities and Differences Between Asian and European Work Ethics(01:09:05) The Benefits of the Chinese Education System(01:16:10) What is the Best First Step Into the Chinese Market?Podcast Links:Podcast Website: Community: Partner: Soschner: Twitter: Linkedin: Episodes: on YouTube: the show (
Part 7 of the Year in Review Recording.1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutFormula 1 FuelsHand SanitizationOpen Source andTechnologyI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Martin PopilkaDenis RoioVideo to the Episode: Martin Popilka – Pivoting from Formula 1 Race Fuels to Hand sanitizer During the Pandemic(05:30) Hand Sanitizer as a Service for Companies(08:00) Data Collection and GDPR Compliance(11:15) Plans for 2022(12:00) Challenges of Running 3 Companies at the same time(15:15) P1 Fuels(21:30) Hand sanitizing to Stay Healthy – Will it Stay After the Pandemic?(25:15) How Was the Experience of Recording 7:30 Hours Straight?(33:12) Denis Roio – Open Source(46:00) Techies against TechnocracyPodcast Links:Community Partner: Soschner: Community: Twitter: Linkedin: Episodes: on YouTube: Website: the show (
Part 6 of the Year in Review Recording.1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutNFTsMetaverseNanoMetaGamesAustrian Entrepreneurship WeekFrom Morning Moonshots to Future WeeklyApple & Spotify Podcast AlgorithmsI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Paul PolterauerPhilipp PeinsoldMarkus RaunigVideo to the Episode: What are NFTs?(03:42) The Metaverse(04:08) More about NFTs(07:20) NanoMetaGames(17:00) NFTs in Games(19:13) NFT and digital collectibles from games(22:57) Usecases for NFT (23:53) When You Have Just 1 Wine and 1 NFT…(25:09) What Do a Shirt and an NFT Have in Common?(27:45) What Legal Challenges do NFTs Face Today?(34:21) NanoMetaGames – Outlook for 2022(36:00) Markus Raunig – Austrian Startups – How was 2021?(37:00) The Austrian Entrepreneurship Week(39:37) From Morning Moonshots to Future Weekly(41:00) The backstory to Future Weekly – How did it all start?(43:45) The Three Biggest Success @ Future Weekly(45:39) The Apple & Spotify Charts Algorithm(48:26) Outlook for 2022 Podcast Links:Community Partner: Soschner: Community: Twitter: Linkedin: Episodes: on YouTube: Website: the show (
Part 5 of the Year in Review Recording.1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutThe Effects of the Pandemic on Business LifeThe Future of ADCs in OncologyMental HealthPsychedelic Drug DevelopmentGilgamesh Pharmaceutical, Christian Angermayer, and Atai Life ScienceAs well as Podcast notesI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Walter StockingerYoni FalksonVideo to the Episode: – Walter Stockinger - Introduction Hadean Ventures(01:00) – Success 2022 – Hadean Ventures(03:00) – Personal Interactions Matter(03:36) – Work-Life at Hadean Ventures During the Pandemic(05:18) – The Effects of the Pandemic on Travelling and the Learnings that Came with it(07:18) – Portfolio Success in 2021(11:52) – Difference of Ticket and Round Sizes in Europe and the US(14:00) – Availability of Capital on the Market for Life Science Projects(17:11) – Future Potential of ADCs in Oncology(23:51) – The Future of mRNA Vaccines(28:47) – Outlook for 2022(30:00) – Yoni Falkson – Introduction(31:05) – Gilgamesh Pharmaceutical and Podcast notes(33:38) – Psychedelic Drug Development – Players on the field(35:52) – Fundraising in the United States during the Pandemic(38:04) – The Psychedelic Drug Development Area(40:50) – Development of Mental Health in the US(44:10) – Microbiome, Mental Health, and Diagnostics(47:44) – Mission of Podcast Notes(51:35) – Podcast notes, Beginner’s Mind, and the Antibacterial Space(54:23) - The Podcast Notes Community(55:37) The USP of Podcast Notes(56:21) Outlook for 2022 – Yoni FalksonPodcast Links:Community Partner: Soschner: Community: Twitter: Linkedin: Episodes: on YouTube: Website: the show (
Part 4 of the Year in Review Recording.1 hour minutes of inspiring conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutBiotech in AustriaCulture of SuccessBusiness Angels, Investment and Market PerspectiveCustomer Needs and EntrepreneurshipI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Albert MissbichlerPeter Llewellyn-DaviesVideo to the Episode: Opening Christian Soschner / Albert Missbichler(02:00) Peter Llewellyn-Davies Biotech in Austria(03:22) How was 2021 for Life Science Entrepreneurs?(05:12) How was 2021 for Biotech Austria?(06:45) The situation of Life Science Infrastructure in Austria(08:00) Lab Space in Austria(09:30) Europe Needs a Culture of Success(12:25) English Proficiency in Austria(14:08) Agenda 2022 – Biotech Austria – 3 Main Goals(16:30) Goal #4: Availability of Capital for Life Science Investments(18:10) Goal #5: Availability of Funding for Clinical Trials(19:30) Goal #6: Have Fun(20:15) Astrid Wollard / Christian Soschner / Matthias Tarasiewicz– Education – Health and Financial Literacy – Beginner’s Mindset(25:30) Why Beginner’s Mind Matters More Than Ever(28:18) The Entrepreneurial Spirit in Oxford(30:05) How Did the Start-Up Scene in Europe Evolve since the 90s?(32:25) Albert Missbichler – Entrepreneurship & Business Angel in Life Science(35:00) Fianostics – Diagnostics during Covid(37:25) From Prototype Stage to Market Entry(38:35) How Important Is Market and Financing Expertise in the Early Stages of a Company?(43:04) Entrepreneurship Mindset and Customer Needs(47:00) Outlook to 2022 – Importance of Meeting in Real Life(49:20) Direct Contact to Customers in the Digital World(52:00) Content Marketing Helps to Build Trust Online(56:30) How Building Business Relationships Changed During the PandemicPodcast Links:Community Partner: Soschner: Community: Twitter: Linkedin: Episodes: on YouTube: Website: the show (
Part 3 of the Year in Review Recording.1 hour 15 minutes of exciting conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutContent Marketing with a PodcastLife Science Industry in AustriaContent Marketing and Social Media for B2B BusinessesHistory of the Vienna Stock ExchangeI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Christian SoschnerJohannes SarxPhilipp HainzlStefanie RöselJulia ReschVideo to the Episode: Christian Soschner & Stefanie Rösel – Podcast & Content Marketing(03:45) The Gary V. Content Strategy Applied at the Podcast(05:30) What Kind of Companies Can Use A Podcast for Their Marketing Purposes?(07:15) Valuations – Quo Vadis?(11:35) Macro Trends & Market Crashes(17:15) Johannes Sarx and Philipp Hainzl – How Did Life Science Evolve in the Last 10 Years in Austria – Audio Only(18:00) More than 1,000 Life Science Companies in Austria(22:35) Marinomed, Tamirna, or Valneva – Companies that started before 2008 in Austria (25:35) Expectations for 2022 – Will the Industry Move Forward at the Same Speed Like in 2020-21?(28:45) EIT Health – Co-Location Center in Vienna(30:10) In-Person Events in Austria in 2022(33:00) Stefanie Rösel – Life Science Content Marketing & Social Media(35:35) How The Pandemic Changed The Behaviour in Business on Social Media(37:16) The Digital Presence of People and Companies Matters More Than Ever(39:45) Why Online Content Marketing Matters for B2B Companies (42:41) The Most Important Platforms for B2B Companies in 2022(44:00) Biggest Lesson From 2021(45:50) Outlook for 2022 – Content marketing(46:35) How Will the Transition von Web 2.0 to Web 3.0 affect Content Marketing(51:45) Julia Resch – Vienna Stoch Exchange – 250 Years(52:35) The Austrian Stock Market in 2021 – 40% Performance(53:45) The European IPO Market(54:15) Life Science and the European Stock Market(55:40) Industries on the Austrian Stock Exchange(56:35) Investment Trends from the Austrian Stock Market Perspective(57:50) Digital Assets on the Stock Markets (01:01:35) Outlook 2022 on the Stock Market (01:03:45) Matthias & Astrid - Overview over Topics from Year in Review(01:07:35)  What was going on in Tech in 2021(01:12:35) Content Marketing for ProfilingPodcast Links:Community Partner: Soschner: Community: Twitter: Linkedin: Episodes: Website: https://www.lifescienceget2getherSupport the show (
Part 2 of the Year in Review Recording. 1 hour 15 minutes of exciting conversations with speakers from previous podcast episodes and business partners of the hosts. What was hot in 2021, and what do our speakers expect for 2022?In this episode, we talk aboutHealth Literacy and the Healthcare SystemVenture Capital in 2021Digitalization in Drug DevelopmentThe Golden Age of BiotechHome Office – How Work-Life will Look like in the Post Pandemic WorldI hope you enjoy the conversation the same way I did.Who are the Experts in this episode:Bettina ReslSascha BergerTilmann BuerckstuemmerThomas MoserKimberly CornfieldVideo to the Episode: Bettina Resl - Christmas Greetings(03:11) Review of 2021  - Challenges for the Healthcare System in 2021 Beyond Covid 19(06:32) Healthy Habits are the First Step to Longevity(07:32) How Do Pharma Reach Patients?(09:12) The Importance of Health Literacy – Concept and Strategies to Improve Health Literacy for the People(16:56) What Happens to Home Office in a Post-Pandemic World(20:00) Sascha Berger – Recap of 2021(21:45) Significant closings in the Life Science VC world during the pandemic(22:57) Lasting Effects of the Capital Flow Towards Life Science(25:20) Will the Development Speed in the Pharma Industry in 2020/21 be Lasting?(29:17) The Digital Revolution – Does it Affect the Dealflow of Life Science VCs?(31:55) Outlook for 2022(32:25) Conference Plans for 2022(33:29) Thomas Moser and Tilmann Buerckstuemmer – Aelian Biotechnology(35:33) Aelian Biotechnology – This was 2021(36:00) Bit.BioDiscovery – Finding New Cell Types – The Holy Grail of Biology(37:14) Outsourcing Trend for Pharma and Biotech Companies(38:00) Trend to Digitalisation(39:38) Data – Is it More Signal or More Noise?(41:39) CRISPR - Trends(42:40) The Golden Age of Biotech(44:18) What is the Big Goal for The Holy Grail of Biology?(46:34) Golden Age of Biotech or Bubble Territory?(47:39) Increasing Health and Financial Literacy for the Common Good of Society(48:18) Data Security in Gene Editing(49:42) Paradigm Shift in Data Storage(54:38) Outlook for 2022 – Aelian Biotech(57:00) Astrid Wollard and Matthias Tarasiewicz – Recap of 2021(58:51) Talent Shortage(01:01:15) Web 2.0 vs. Web 3.0(01:01:55) Use-Cases in Web 3.0 Beyond Token(01:02:00) Kimberly Cornfield - Intro(01:02:30) Research Activities at the UCL in Web 3.0 and Beyond(01:04:00) European Research & Innovation at the UCL(01:05:00) Effects of the Brexit on European Collaboration with British Universities(01:07:00) How Did Collaborations between Universities Change With the Pandemic?(01:08:29) Outlook for 2022 – Focused Research Areas(01:10:20) Big Trends in Research in 2021(01:11:00) Artificial Intelligence, Democracy, and Education(01:11:48) Astrid Woollard – Potential of Artificial Intelligence(01:13:00) Matthias Tarasiewicz – AI and Machine Learning in this decade(01:15:32) Kimberly Cornfield – Horizon Europe 2022Support the show (
This is Part 1 of the 7,5 hours conversations marathon before Christmas with speakers from previous podcast episodes and business partners of the host and co-host of the Podcast.In this episode, we talk aboutCovid19 CryptocurrenciesCybersecurity andMerger & AcquisitionI hope you enjoy the conversation the same way as I did.Who are the Experts in this episode:Astrid WoollardDusica LukacMatthias TarasiewiczIrénée RobinVideo to the episode: Opening(03:15) Astrid Woollard – Foundation of SMAPE Capital and Blockchain Technology(04:31) How to Manage 80-100 Opportunities per month(05:39) Focus of SMAPE Capital(08:00) What is DAO?(08:35) Selling of one of the First Copies of the US Constitution for 42.5 Million Dollar(10:30) Potential of DAO in Fundraising for Startups(11:30) Astrid’s Outlook for 2022(13:00) Price Predictions for BTC and ETH for 2022(14:15) Dusica Lukac”The Transaction Diva”  – M&A in 2021(20:30) M&A in Crypto in 2022(22:30) Great Transactions in 2022(24:30) Outlook for 2022(26:00) Which Sector will Dominate 2022?(28:15) Matthias Tarasiewicz – Covid 19 and Cybersecurity(36:30) How to Raise Awareness for the Need of Cybersecurity?(40:00) Messenger Services like Whatsapp, Telegram or Signal and Cybersecurity(42:15) How Billionaire Entrepreneurs Influence the Public Opinion about Tech(44:15) Irénée Robin – Vaccines and Therapeutics against SARS CoV 2(46:45) Expectations on the development of travel restrictions(47:30) How Did the Drug Development and Vaccine Space evolve since September 2020?(48:30) The 3 Legs of a Pandemic Response(55:15) The Success of Pharma in the Pandemic Response(58:30) Difference Between Tamiflu and c Antiviral Drugs for the SARS CoV 2 Response(01:03:40) Matthias Tarasiewicz - Supply Chain Issues as a Result of the Pandemic – Hardware, Chips, Drugs(01:08:40) Supply Chains in Pharma in 2021 (01:11:45) Open Sourcing Medical Devices(01:13:00) Why Did the Development of Therapeutics Take Longer Than Vaccines?Podcast Links:Community Partner: Soschner: Community: Twitter: Linkedin: Episodes: on YouTube: Website: the show (
Download from Google Play
Download from App Store